FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...
Rhythm Pharmaceuticals (NASDAQ:RYTM) announced that the U.S. Food and Drug Administration has approved IMCIVREE ...
Acquired hypothalamic obesity is typically precipitated by hypothalamic insult from tumors, treatment, trauma, stroke, or ...
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or ...
European Commission decision anticipated in second quarter of 2026 --BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc.
By Sneha S K and Sahil Pandey March 20 (Reuters) - The U.S. Food and Drug Administration expanded the use of Rhythm ...
European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutica ...
First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfuncti ...
Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.
PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, announced that it was selected by Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results